- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00468000
Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia (RESTORE-CLI)
Use of Ixmyelocel-T (Formerly TRC Autologous Bone Marrow Cells) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia
This study is designed to evaluate the safety and efficacy of autologous Vascular Repair Cells (VRC) for patients with peripheral arterial disease as a treatment for critical limb ischemia.
The double-blind study is expected to enroll 150 patients, randomized into two patient groups. The treatment group will receive intramuscular (IM) injections of the VRCs into the affected limb; the control group will receive intramuscular injections with an electrolyte solution (without cells). Both groups will receive the standard of care appropriate for their medical condition.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The study will assess the safety and ability of Aastrom TRC autologous bone marrow cells to restore peripheral blood flow affected by critical limb ischemia.
Peripheral arterial disease (PAD), also known as Peripheral Vascular Disease (PVD), occurs when peripheral arteries are damaged by arterial hypertension and/or by the formation of atherosclerotic plaques. PAD is a chronic disease that progressively constricts arterial circulation of limbs. The term critical limb ischemia (CLI) is used for all patients with chronic ischemia rest pain, ulcers, or gangrene in limbs attributable to objectively proven PAD. These sequelae represent the end stage of PAD. PAD is associated with several other clinical conditions, i.e. hypertension, cardiovascular disease, hyperlipidemia, diabetes, tobacco use, obesity and stroke.
The double-blind study is expected to enroll 150 patients, randomized into two patient groups. The treatment group will receive intramuscular injections of the TRC product into the affected limb; the control group will receive intramuscular injections with an electrolyte solution (without cells). Both groups will receive the standard of care appropriate for their medical condition.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35211
- Cardiology, P.C.
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85006
- Arizona Heart Institute
-
-
California
-
San Francisco, California, Estados Unidos, 94143
- University of California, San Francisco
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32608
- Malcolm Randall Veterans Administration Medical Center, part of the North Florida/South Georgia Veterans Health System
-
Miami, Florida, Estados Unidos, 33136
- University of Miami/Miller School of Medicine
-
-
Illinois
-
Maywood, Illinois, Estados Unidos, 60153
- Loyola University Stritch School of Medicine
-
Springfield, Illinois, Estados Unidos, 62702
- Southern Illinois University School of Medicine
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46260
- The Care Group, Llc
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48106
- St. Joseph Mercy Hospital
-
Ann Arbor, Michigan, Estados Unidos, 48105
- VA Ann Arbor Healthcare System
-
Flint, Michigan, Estados Unidos, 48507
- Michigan Vascular Research Center
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Minneapolis Heart Institute Foundation
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03756
- Dartmouth-Hitchcock Memorial Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27514
- University of North Carolina Hospitals
-
-
Ohio
-
Toledo, Ohio, Estados Unidos, 43606
- Jobst Vascular Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Oklahoma University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213
- University of Pittsburgh Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232-2735
- Vanderbilt University Medical Center
-
-
Texas
-
San Antonio, Texas, Estados Unidos, 78205
- Peripheral Vascular Associates
-
Temple, Texas, Estados Unidos, 76508
- Scott and White Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Males and females, 18-90 years of age
- Diagnosis of CLI
- Infrainguinal occlusive disease, without options for revascularization
- No surgical interventions planned
- Life expectancy of 2 years
- Normal organ and marrow function
- Patients with controlled blood pressure (≤ 180/110 mmHg) and established anti-hypertensive therapy
- Established anti-platelet therapy
Exclusion Criteria:
- Poorly controlled diabetes mellitus (hemoglobin A1c [HbA1c] > 10%)
- Aortoiliac disease with > 50% stenosis
- Wounds with severity greater than Grade 3 on the Wagner Scale
- Any known failed ipsilateral revascularization within 2 weeks of enrollment
- Previous amputation of the talus, or above in the target limb
- Life-threatening ventricular arrhythmia; unstable angina; or, myocardial infarction within 4 weeks of enrollment
- Severe congestive heart failure (CHF) (i.e. New York Heart Association [NYHA] Stage IV)
- Receiving treatment with hematopoietic growth factors
- Infection of the involved extremity(ies)
- Active wet gangrenous tissue
- Require uninterruptible anticoagulation therapy
- Blood clotting disorder
- Cancer
- End stage renal disease requiring dialysis for more than 6 months prior to enrollment
- Pregnant or lactating
- Having received medication for thrombolytic therapy (e.g. rTPA or other enzymatic clot busters) within 30 days prior to enrollment
- Undergoing hyperbaric oxygen treatment within 2 weeks of enrollment
- Concomitant wound treatments with growth factors or tissue engineered products
- Receiving anti-angiogenic drugs
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Ixmyelocel-T
The treatment arm of the study will receive injections of the study cellular product.
|
IM injection
|
Comparador de placebos: Placebo
The control arm of the study will receive placebo injections.
|
IM Injection
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Safety of TRCs in patients with CLI(key safety parameters include vital signs, physical exams, laboratory results, assessment of aspiration and injection sites, adverse events, major amputations, wounds presence(size and grading using the Wagner scale)
Periodo de tiempo: throughout trial
|
throughout trial
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Composite efficacy endpoint assessing time to treatment failure(failure defined as major amputation, doubling of wound size, and new gangrene)
Periodo de tiempo: Day 7 and Months 3, 6, 9, 12
|
Day 7 and Months 3, 6, 9, 12
|
Percentage of patients failing treatment
Periodo de tiempo: Day 7, and Months 3,6,9, and 12
|
Day 7, and Months 3,6,9, and 12
|
Time to major amputation
Periodo de tiempo: Day 7 and Month 3, 6, 9, and 12
|
Day 7 and Month 3, 6, 9, and 12
|
Percentage of patients undergoing major amputation
Periodo de tiempo: Day 7 and Months 3, 6, 9, 12
|
Day 7 and Months 3, 6, 9, 12
|
Incidence of revascularization interventions throughout duration of study
Periodo de tiempo: Day 7 and Months 3,6,9,12
|
Day 7 and Months 3,6,9,12
|
Incidence of bypass surgery for patients throughout duration of study
Periodo de tiempo: Day 7 and Months 3,6,9,12
|
Day 7 and Months 3,6,9,12
|
Healing of all wounds in the target limb
Periodo de tiempo: Day 7 and Months 3,6,9,12
|
Day 7 and Months 3,6,9,12
|
Ankle and/or toe pressure and ankle brachial pressure index and/or toe brachial index
Periodo de tiempo: Day 7 and Months 3,6,9,12
|
Day 7 and Months 3,6,9,12
|
Pain, as measured by visual analog scale(VAS)
Periodo de tiempo: Day 7 and Months 3,6,9,12
|
Day 7 and Months 3,6,9,12
|
The King's College Vascular Quality of Life Questionnaire
Periodo de tiempo: Baseline and Months 6 and 12
|
Baseline and Months 6 and 12
|
Walking distance as measured by six-minute walk test(with or without walking device)
Periodo de tiempo: Baseline and Month 12
|
Baseline and Month 12
|
Concurrent Meds for trends
Periodo de tiempo: Day 7 and Months 3, 6, 9, 12
|
Day 7 and Months 3, 6, 9, 12
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Anthony J Comerota, MD, Jobst Vascular Center
Publicaciones y enlaces útiles
Publicaciones Generales
- Moazzami B, Mohammadpour Z, Zabala ZE, Farokhi E, Roohi A, Dolmatova E, Moazzami K. Local intramuscular transplantation of autologous bone marrow mononuclear cells for critical lower limb ischaemia. Cochrane Database Syst Rev. 2022 Jul 8;7(7):CD008347. doi: 10.1002/14651858.CD008347.pub4.
- Powell RJ, Marston WA, Berceli SA, Guzman R, Henry TD, Longcore AT, Stern TP, Watling S, Bartel RL. Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. Mol Ther. 2012 Jun;20(6):1280-6. doi: 10.1038/mt.2012.52. Epub 2012 Mar 27.
- Powell RJ, Comerota AJ, Berceli SA, Guzman R, Henry TD, Tzeng E, Velazquez O, Marston WA, Bartel RL, Longcore A, Stern T, Watling S. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia. J Vasc Surg. 2011 Oct;54(4):1032-41. doi: 10.1016/j.jvs.2011.04.006. Epub 2011 Jul 31.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- ABI-55-0610-1
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Enfermedad arterial periférica
-
Dartmouth-Hitchcock Medical CenterDartmouth CollegeTerminadoPresión arterial | Anestesia | Línea ArterialEstados Unidos
-
Auburn UniversityActivo, no reclutandoDormir | Presión arterial | Disfunción endotélica | Racismo | Rigidez ArterialEstados Unidos
-
AHEPA University HospitalTerminadoRigidez arterial | Monitoreo ambulatorio de la presión arterialGrecia
-
Unity Health TorontoTerminadoRigidez arterial, presión arterialCanadá
-
BLZ Technology (Wuhan) Co.,LtdAún no reclutandoPresión arterial | Anestesia general | Línea Arterial | La frecuencia del pulso
-
Marissa JarosinskiReclutamientoEnfermedad arterial periférica oclusiva | Enfermedad vascular periférica | Enfermedad Arterial Periférica | Clopidogrel, metabolismo deficiente de | Enfermedad ArterialEstados Unidos
-
CID S.p.A.Meditrial Europe Ltd.Aún no reclutandoEnfermedad arterial periférica oclusiva | Enfermedad Arterial PeriféricaItalia
-
Istituto Auxologico ItalianoReclutamientoHipertensión arterial | Monitoreo ambulatorio de la presión arterial | Determinación de la presión arterial | Monitoreo de la presión arterial en el hogarItalia
-
ROX Medical, Inc.TerminadoHipertensión | Presión Arterial, Alta | Presión Arterial, Resistente | Presión Arterial, No ControladaReino Unido, Países Bajos, Bélgica
-
University of JyvaskylaBusiness Finland; Finnish Foundation for Cardiovascular Research; Harvia Finland...TerminadoPresión arterial | Factor de riesgo cardiovascular | Rigidez arterialFinlandia
Ensayos clínicos sobre Ixmyelocel-T
-
University of MichiganVericel CorporationTerminadoPérdida ósea alveolarEstados Unidos
-
Biotronik SE & Co. KGTerminadoInsuficiencia cardiaca | BradicardiaDinamarca, Hong Kong, Austria, Alemania, Bélgica
-
Biotronik SE & Co. KGTerminadoLa fibrilación ventricular | Taquicardia ventricularAlemania, República Checa
-
University of California, BerkeleyUniversity of Nevada, Reno; World Bank; L'Office National de Nutrition, MadagascarReclutamientoEl desarrollo de la primera infanciaMadagascar
-
University of South FloridaNational Cancer Institute (NCI)ReclutamientoCáncer | Obesidad, Infancia | SupervivenciaEstados Unidos
-
Hebei Senlang Biotechnology Inc., Ltd.ReclutamientoLinfoma | Mieloma múltiple | Leucemia linfoblástica agudaPorcelana
-
Everett MeyerNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...TerminadoLinfoma No Hodgkin | Leucemia mieloide aguda | Leucemia aguda | Leucemia mielógena aguda | Leucemia mielógena crónica | Síndromes mielodisplásicos (SMD) | Leucemia linfoblástica aguda (LLA) | Leucemia mieloide crónica | Síndrome mieloproliferativoEstados Unidos
-
The First Affiliated Hospital of Guangdong Pharmaceutical...Guangzhou Anjie Biomedical Technology Co., Ltd.DesconocidoCáncer de esófago avanzadoPorcelana
-
Yooyoung Pharmaceutical Co., Ltd.TerminadoDislipidemiasCorea, república de
-
Nexcella Inc.Aún no reclutandoAmiloidosis de cadena ligera (AL)Estados Unidos